Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer

Diseases of the Colon and Rectum

Volumn 41, Issue 3, 1998, Pages 310-315

  Waldman, S A ^a   Cagir, B ^b   Rakinic, J ^b   Fry, R D ^b   Goldstein, S D ^b   Isenberg, G ^b   Barber, M ^a   Biswas, S ^a   Minimo, C ^a   Palazzo, J ^a   Park, P K ^b   Weinberg, D ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biomarker; Colorectal tumors; Guanylyl cyclase C; Histopathology; Micrometastases; Reverse transcriptase polymerase chain reaction; Staging, colorectal cancer

Indexed keywords

GUANYLATE CYCLASE; GUANYLATE CYCLASE C; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; GUANYLATE CYCLASE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, PEPTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031938629     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02237484     Document Type: Article

References (29)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1991;41:19-36.
2. Greenwald P. Colon cancer overview. Cancer 1992; 70(Suppl 5):1206-15.
3. Cresanta JL. Epidemiology of cancer in the United States. Prim Care 1992;19:419-41.
4. Jessup JM, McGinnis LS, Steele GD Jr, Menck HR, Winchester DP. The national cancer data base report on colon cancer. Cancer 1996;78:918-26.
5. Beatty JD. Immunotherapy of colorectal cancer. Cancer 1992;75(Suppl 5):1425-33.
6. Shapiro S. Goals of screening. Cancer 1992;75(Suppl 5);1252-8.
7. Smart CR. Screening and early detection. Cancer 1992; 75(Suppl 5):1246-51.
8. Pihl E, Hughes ES, McDermott A, Milne BJ, Price AB. Disease-free survival and recurrence after resection of colorectal cancer. J Surg Oncol 1981;16:333-41.
9. Sloane P. Molecules and micrometastases. Lancet 1995; 345:1255-6.
10. Abati A, Liotta LA. Looking forward in diagnostic pathology: the molecular superhighway. Cancer 1996;78: 10-6.
11. Hayashi N, Ito I, Yanagisawa A, et al Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257-9.
12. Rubio CA, Emas S, Nylander G. A critical reappraisal of Dukes' classification. Surg Gynecol Obstet 1977;145: 682-4.
13. Carrithers SL, Parkinson SJ, Goldstein S, Park P, Robertson DC, Waldman SA. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 1994;107:1653-61.
14. Carrithers SL, Parkinson SJ, Goldstein SD, Park PK, Urbanski RW, Waldman SA. Escherichia coli heat-stable enterotoxin receptors: a novel marker for colorectal tumors. Dis Colon Rectum 1996;39;171-81.
15. Carrithers S, Barber MT, Biswas S, et al. Guanylyl cyclase C is a specific marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA 1996;93:14827-32.
16. Fisher ER, Sass R, Palekar A, Fisher B, Wolmar N. Dukes' classification revisited: findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). Cancer 1989;64:2354-60.
17. Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988;31:33-41.
18. Hermanek P, Guggenmoos-Holzmann I, Gall FP. Prognostic factors in rectal carcinoma: a contribution to the further development of tumor classification. Dis Colon Rectum 1989;32:593-9.
19. De Leon MP, Sant M, Micheli A, et al. Clinical and pathologic prognostic indicators in colorectal cancer: a population-based study. Cancer 1992;69:626-35.
20. Greenson JK, Isenhart CE, Rice R, Mojzisk C, Houchens D, Martin EW. Identification of occult micrometastases in pericolic lymph nodes of Dukes' B colorectal cancer patients using messenger antibodies against cytokeratin and CC49. Cancer 1994;73:563-9.
21. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523-7.
22. Maehara Y, Oshiro T, Endo K, et al. Clinical significance of occult micrometastasis in lymph nodes from patients with early gastric cancer who die of recurrence. Surgery 1996;119:397-402.
23. Chen ZL, Perez S, Holmes EC, et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 1993;85:493-8.
24. Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and rectal cancer. Semin Oncol 1995;22:472-7.
25. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
26. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
27. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluoruracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
28. O'Connell M, Maillaird JA, MacDonald J, et al. An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer [absract]. Proc Am Soc Clin Oncol 1993;12:A552.
29. Erlichmann C, Marsoni S, Seitz J, et al. Event free and overall survival is increased by FUFA in resected B and C colon cancer: a prospective pooled analysis of 3 randomized trials [abtract]. Proc Am Soc Clin Oncol 1994;13:A56.